Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis

Virology

Volumn 383, Issue 1, 2009, Pages 69-77

  Zehbe, Ingeborg ^a   Richard, Christina ^a   DeCarlo, Correne A ^a   Shai, Anny ^b   Lambert, Paul F ^b   Lichtig, Hava ^c   Tommasino, Massimo ^d   Sherman, Levana ^c  

^a THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Apoptosis; Differentiation; E6 prototype; E6 variant; Human papillomavirus 16; Keratinocyte; Proliferation

Indexed keywords

CYTOKERATIN 5; DACTINOMYCIN; PROTEIN E6; PROTEIN P53; VIRUS DNA;

ANOIKIS; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CULTURE; CELL CYCLE; CELL DIFFERENTIATION; DNA DAMAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE TRANSFER; GROWTH DISORDER; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HYPERPLASIA; KERATINOCYTE; LIFE CYCLE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

APOPTOSIS; CELL DIFFERENTIATION; CELL TRANSFORMATION, VIRAL; CELLS, CULTURED; FEMALE; GENETIC VARIATION; HUMAN PAPILLOMAVIRUS 16; HUMANS; KERATINOCYTES; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS;

HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 57149085039     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.09.036     Document Type: Article

References (70)

1. Alfandari J., Shnitman Magal S., Jackman A., Schlegel R., Gonen P., and Sherman L. HPV16 E6 oncoprotein inhibits apoptosis induced during serum-calcium differentiation of foreskin human keratinocytes. Virology 257 (1999) 383-396
2. Asadurian Y., Kurilin H., Lichtig H., Jackman A., Gonen P., Tommasino M., Zehbe I., and Sherman L. Activities of human papillomavirus 16 E6 natural variants in human keratinocytes. J. Med. Virol. 79 (2007) 1751-1760
3. Allen-Hoffmann B.L., Schlosser S.J., Ivarie C.A., Sattler C.A., Meisner L.F., and O'Connor S.L. Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J. Invest. Dermatol. 114 (2000) 444-455
4. Bernard H.U. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J. Clin. Virol. 32 Suppl. 1 (2005) S1-S6
5. Bernard H.U., Calleja-Macias I.E., and Dunn S.T. Genome variation of human papillomavirus types: phylogenetic and medical implications. Int. J. Cancer 118 (2006) 1071-1076
6. Berumen J., Ordonez R.M., Lazcanao E., Salmeron E., Galvan S.C., Estrada R.A., Yunes E., Garcia-Carranca A., Gonzalez-Lira G., and Madrigal-de-la-Campa A. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study. J. Natl. Cancer Inst. 93 (2001) 1325-1330
7. Chakrabarti O., Veeraraghavalu K., Tergaonkar V., Liu Y., Androphy E.J., Stanley M.A., and Krishna S. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J. Virol. 78 (2004) 5934-5945
8. Chen Z., Terai M., Fu L., Herrero R., DeSalle R., and Burk R.D. Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses. J. Virol. 79 (2005) 7014-7023
9. Conrad-Stoppler M., Ching K., Stoppler H., Clancy K., Schlegel R., and Icenogle J. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J. Virol. 70 (1996) 6987-6993
10. del Refugio Gonzales-Losa M., Laviada Mier y Teran M.A., Puerto-Solis M., and Garcia-Carranca A. Molecular variants of HPV16 type 16 among Mexican women with LSIL and invasive cancer. J. Clin. Virol. 29 (2004) 95-98
11. DeCarlo C.A., Escott N.G., Werner J., Robinson K., Lambert P.F., Law R.D., and Zehbe I. Gene expression analysis of interferon kappa in laser capture microdissected cervical epithelium. Anal. Biochem. 381 (2008) 59-66
12. DiMaio D., and Liao J.B. Human papillomaviruses and cervical cancer. Adv. Virus Res. 66 (2006) 125-140
13. Drozdoff V., and Pledger W.J. Commitment to differentiation and expression of early differentiation markers in murine keratinocytes in vitro are regulated independently of extracellular calcium concentrations. J. Cell Biol. 123 (1993) 909-919
14. Ferenczy A., and Franco E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol. 3 (2002) 11-16
15. Filippova M., Song H., Connolly J.L., Dermody T.S., and Duerksen Hughes P.J. The human papillomavirus 16 E6 binds to tumor necrosis factor R1 and protects cells from TNF-induced apoptosis. J. Bio. Chem. 277 (2002) 21730-21739
16. Filippova M., Johnson M.M., Bautista M., Filipov V., Fodor N., Tungteakkhun S.S., Williams K., and Duerksen-Hughes J. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J. Virol. 81 (2007) 4116-4129
17. Foster S.A., Demers G.W., Etscheid B.G., and Galloway D.A. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virology 68 (1994) 5698-5705
18. Flores E.R., Allen-Hoffman B.L., Lee D., Sattler C.A., and Lambert P.F. Establishment of the human papillomavirus type16 (HPV-16) life cycle in an immortalized and human foreskin keratinocyte cell line. Virology 262 (1999) 344-354
19. Flores E.R., Allen-Hoffmann B.L., Lee D., and Lambert P.F. The human papillomavirus Type 16 E7 oncogene is required for the productive stage of the viral life cycle. J. Virol. 74 (2000) 6622-6631
20. Garnett T.O., Filippova M., and Duerksen Hughes P.J. Accelerated degradation of FADD and procaspase-8 in cells expressing human papillomavirus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Diff. 13 (2006) 1915-1926
21. Golan, M., Hizi, A., Resau, J.H., Yaal-Hohoshen, N., Reichman, H., Keydar, I., Tsarfaty, I., 2008. Human Endogenous Retrovirus (HERV-K) Reverse Transcriptase as a Breast Cancer Prognostic Marker. Neoplasia 10, 521-533.
22. Grodzki M., Besson G., Clavel C., Franceschi S., Arslan A., Birembaut P., Tommasino M., and Zehbe I. Increased risk for cervical disease progression of French women infected with the human papillomavirus 16 E6-350G variant. Cancer Epidemiol. Biomarker Prev. 15 (2006) 820-822
23. Halbert C.L., Demers G.W., and Galloway D.A. The E6 and E7 genes of human papillomavirus Type 6 have weak immortalizing activity in human epithelial cells. J. Virol. 66 (1992) 2125-2134
24. Hansen L.A., Woodson R.L., Holbus S., Strain K., Lo Y.C., and Yuspa S.H. The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors. Cancer Res. 60 (2000) 3328-3332
25. Hildesheim A., Schiffman M., Bromley C., Wacholder S., Herrero R., Rodriguez A., Bratti M.C., Sherman M.E., Scarpidis U., Lin Q.Q., Terai M., Bromley R.L., Buetow K., Apple R.J., and Burk R.D. Human papillomavirus type 16 variants and risk of cervical cancer. J. Natl. Cancer Inst. 93 (2001) 315-318
26. Huang S.M., and McCance D.J. Down regulation of the interleukin-8 promoter by human papillomavirus type 16 E6 and E7 through effects on CREB binding protein/p300 and P/CAF. J. Virol. 76 (2002) 8710-8721
27. Hudson J.B., Bedell M.A., McCance D.J., and Laimins L.A. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus Type 18. J. Virol. 64 (1990) 519-526
28. Huitfeldt H.S., Heyden A., Clausen O.P., Thrane E.V., Roop D., and Yuspa S.H. Altered regulation of growth and expression of differentiation-associated keratins in benign mouse skin tumors. Carcinogenesis 12 (1991) 2063-2067
29. Kämmer C., Tommasino M., Syrjanen S., Delius H., Hebling U., Warthorst U., Pfister H., and Zehbe I. Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: implications for cervical disease. Br. J. Cancer 86 (2002) 269-273
30. Kessis T.D., Slebos R.J., Nelson W.G., Kastan M.B., Plunkett B.S., Han S.M., Lorincz A.T., Hedrick L., and Cho K.R. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 3988-3992
31. Kikuchi K., and Yasumoto S. Retention of cell adhesion and growth capability in human cervical cancer cells deprived of cell anchorage. Jpn. J. Cancer Res. 90 (1999) 867-873
32. Koster M.I., and Roop D.R. Mechanisms regulating epithelial stratification. Annu. Rev. Cell Dev. Biol. 23 (2007) 93-113
33. Lagrange M., Charbonnier S., Orfanoudakis G., Robinson P., Zanier K., Masson M., Lutz Y., Trave G., Weiss E., and Deryckere F. Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6. J. Gen. Virol. 86 (2005) 1001-1007
34. Lee C., and Laimins L.A. Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus Type 31. J. Virol. 78 (2004) 12366-12377
35. Lee K., Magalhaes I., Clavel C., Birembaut P., Tommasino M., and Zehbe I. Distribution of human papillomavirus 16 E6, L1, L2 and E2 gene variants in pre-malignant cervical disease. Virus Res. 131 (2008) 106-110
36. Lichtig H., Algrisi M., Botzer L.E., Abadi T., Verbitzkiy Y., Jackman A., Tommasino M., Zehbe I., and Sherman L. HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virology 350 (2006) 216-227
37. Londesborough P., Ho L., Terry G., Cuzick J., Wheeler C., and Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int. J. Cancer 69 (1996) 364-368
38. Mantovani F., and Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20 (2001) 7874-7887
39. Marconi A., Atzei P., Panza C., Fila C., Tiberio R., Truzzi F., Wachter T., Leverkus M., and Pincelli C. FLICE/caspase-8 activation triggers anoikis induced by beta1-integrin blockade in human keratinocytes. J. Cell Sci. 117 (2004) 815-823
40. McCance D.J., Kopan R., Fuchs E., and Laimins L.A. Human papillomavirus type16 alters human epithelial cell differentiation in vitro. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 7169-7173
41. Moody C.A., Fradet-Turcotte A., Archambault J., and Laimins L.A. Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 19541-19546
42. Morgenstern J.P., and Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18 (1990) 3587-3596
43. Nguyen B.C., Lefort K., Mandinova A., Antonini D., Devgan V., Della Gatta G., Koster I M., Zang Z., Wang J., Tommasi di Vignano A., Kitajewski J., Chiorino G., Roop D.R., Missero C., and Dotto G.P. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev. 20 (2006) 1028-1042
44. Ormerod M.G., Payne A.W., and Watson J.V. Improved program for the analysis of DNA histograms. Cytometry 8 (1987) 637-641
45. Park J.S., Kim E.J., Lee J.Y., Sin H.S., Namkoong S.E., and Um S.J. Functional inactivation of p73, a homologue of p53 tumour suppressor protein, by human papillomavirus E6 proteins. Int. J. Cancer 91 (2001) 822-827
46. Patel D., Huang S.M., Baglia L.A., and McCance D.J. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 18 (1999) 5061-5072
47. Picconi M.A., Alonio L.V., Sichero L., Mbayed V., Villa L.L., Gronda J., Campos R., and Teyssie A. Human papillomavirus type 16 variants in Quechua aboriginals from Argentina. J. Med. Virol. 69 (2003) 546-552
48. Poumay Y., and Coquette A. Modelling the human epidermis in vitro: tool for basic and applied research. Arch. Dermatol. Res. 298 (2007) 361-369
49. Ruiz S., Santos M., Segrelles C., Leis H., Jorcano J.L., Berns A., Paramio J.M., and Vooijs M. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development 131 (2004) 2737-2748
50. Sathish N., Abraham P., Peedicayil A., Sridharan G., and Chandi G. HPV16 E6 sequence variations in Indian patients with cervical neoplasia. Cancer Lett. 229 (2005) 93-99
51. Scheffner M., Wernes B.A., Huibregtse J.M., Levine A.J., and Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 (1990) 1129-1136
52. Seedorf K., Krammer G., Dürst M., Suhai S., and Röwekamp W.G. Human papillomavirus 16 DNA sequence. Virology 145 (1985) 181-185
53. Sherman L., and Schlegel R. Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16. J. Virol. 70 (1996) 3269-3279
54. Sichero L., Ferreira S., Trottier H., Duarte-Franco E., Ferenczy A., Franco E.L., and Villa L.L. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int. J. Cancer 120 (2007) 1763-1768
55. Song S., Pitot H.C., and Lambert P.F. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J. Virol. 73 (1999) 5887-5893
56. Trask D.K., and Muller M.T. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 1417-1421
57. Ueno T., Sasaki K., Yoshida S., Kajitani N., Satsuka A., Nakamura H., and Sakai H. Molecular mechanism of hyperplasia induction by human papillomavirus E7. Oncogene 25 (2006) 4155-4164
58. Veldman T., Liu X., Yuan H., and Schlegel R. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 8211-8216
59. Villa L.L., Sichero L., Rahal P., Caballero O., Ferenczy A., Rohan T., and Franco E.L. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J. Gen. Virol. 81 (2000) 2959-2968
60. Woodworth C.D., Cheng S., Simpson S., Hamacher L., Chow L.T., Broker T.R., and DiPaolo J.A. Recombinant retroviruses encoding human papillomavirus type 18 E6 and E7 genes stimulate proliferation and delay differentiation of human keratinocytes early after infection. Oncogene 7 (1992) 619-626
61. Xi L.F., Demers G.W., Koutsky L.A., Kiviat N.B., Kuypers J., Watts D.H., Holmes K.K., and Galloway D.A. Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J. Infect. Dis. 172 (1995) 747-755
62. Xi L.F., Koutski L.A., Galloway D.A., Kuypers J., Hughes J.P., Wheeler C.M., Holmes K.K., and Kiviat N.B. Genomic variation of human papillomavirus type 16 and risk for high-grade cervical intraepithelial neoplasia. J. Natl. Cancer Inst. 89 (1997) 796-802
63. Xi L.F., Kiviat N.B., Hildesheim A., Galloway D.A., Wheeler C.M., Ho J., and Koutski L.A. Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J. Natl. Cancer Inst. 98 (2006) 1045-1052
64. Yamada T., Manos M.M., Peto J., Greer C.E., Munoz N., Bosch F.X., and Wheeler C.M. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J. Virol. 71 (1997) 2463-2472
65. Zehbe I., Wilander E., Delius H., and Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 58 (1998) 829-833
66. Zehbe I., Voglino G., Delius H., Wilander E., and Tommasino M. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 352 (1998) 1441-1442
67. Zehbe I., Voglino G., Wilander E., Delius H., Edler L., Klimek F., Andersson S., and Tommasino M. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res. 61 (2001) 608-611
68. Zehbe I., Tachezy R., Mytilineos J., Voglino G., Mikyskova I., Delius H., Gissmann L., Wilander E., and Tommasino M. Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int. J. Cancer 94 (2001) 711-716
69. Zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim. Biophys. Acta 1288 (1996) 55-78
70. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2 (2002) 342-350